Zobrazeno 1 - 10
of 507
pro vyhledávání: ''
Autor:
Junji Uchino, Akira Nakao, Osamu Hiranuma, Yusuke Chihara, Masahiro Iwasaku, Takashi Kijima, Chieko Takumi, Yoshiko Kaneko, Takahiro Yamada, Masafumi Takeshita, Makoto Hibino, Yoshie Morimoto, Koichi Takayama, Kenji Morimoto, Takayuki Takeda, Tadaaki Yamada, Yasuhiro Goto, Hiroyuki Yamaguchi, Takashi Yokoi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
Combination therapy of immune checkpoint inhibitors and chemotherapy is considered to be one of the standard treatment options for patients with advanced non-small-cell lung cancer (NSCLC). However, the clinical significance of immune checkpoint inhi
Autor:
Hidetoshi Kasuya, Bierta E. Barfod, Toru Serizawa, Yasunori Sato, Masaaki Yamamoto, Yoshinori Higuchi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 149
There is little information on stereotactic radiosurgery (SRS) results for brain metastases (BMs) in lung cancer patients ≥75 years of age. We aimed to reappraise whether SRS results for patients ≥75 (very elderly) differ from those of patients w
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 150
Large cell neuroendocrine carcinoma (LCNEC) is a rare pulmonary malignancy with clinicopathologic features of both non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Given the paucity of available data regarding LCNEC management, w
Publikováno v:
Lung Cancer
Lung Cancer, Elsevier, 2020, 145, pp.71-75. ⟨10.1016/j.lungcan.2020.04.025⟩
Lung Cancer, Elsevier, 2020, 145, pp.71-75. ⟨10.1016/j.lungcan.2020.04.025⟩
Immunotherapy with immune checkpoint inhibitors (ICIs) represents a breakthrough in lung cancer treatment. The efficacy of monoclonal antibodies targeting the programmed cell death protein 1 (PD-1), its ligand L1 (PD-L1), and cytotoxic T-lymphocyte-a
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Introduction Several obstacles may delay receipt of targeted treatment in patients with anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC). This study examined the factors associated with delayed initiation of ALK inhibitor
Autor:
Michael Cabanero, Xuyang Song, Rosalyn A. Juergens, Penelope A. Bradbury, Phillip A. Dennis, John Hilton, P. Brown-Walker, Desiree Hao, John R. Goffin, Sebastien J. Hotte, Anna Tomiak, Gwyn Bebb, Scott A. Laurie, Andrew Robinson, Martin Smoragiewicz, Christian K. Kollmannsberger, I. Gauthier, Moustapha Tehfe, Xiaoqun Sun, Peter M. Ellis, Dongsheng Tu, Paul Wheatley-Price, Mihaela Mates, Janessa Laskin, Glenwood D. Goss, Lesley Seymour, Ming-Sound Tsao
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into one of six dose levels (DL) of Du
Publikováno v:
Lung Cancer
Objective Investigate the spectrum of radiographic patterns of radiation pneumonitis (RP) in lung cancer patients and identify imaging markers for high-grade RP and RP-related death. Methods Eighty-two patients with lung cancer treated with conventio
Autor:
Matteo Giaj Levra, V. Grumberg, Anne-Françoise Gaudin, John R. Penrod, Jean-Baptiste Assié, Christos Chouaid, François-Emery Cotté, Ronan Jolivel, B. Jouaneton, C. Calvet, Romain Corre
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 140
Objectives Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolum
Autor:
Kaiyan Chen, Xiaoqing Yu, Zhiyu Huang, Yun Fan, Guoping Cheng, Yanjun Xu, Fanrong Zhang, Guanxia Zhu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 142
The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with uncommon EGFR alterations was reported to derive clinical benefit from PD-1 blockade
Autor:
Hui Sun, Chao Zhao, Wei Li, Xiaoxia Chen, Caicun Zhou, Chunyan Wang, Shuo Yang, Fengying Wu, Yayi He, Xuefei Li, Yiwei Liu, Shiqi Mao, Yingying Pan, Shengxiang Ren, Xiaofei Yu, Chunxia Su, Qian Liu, Yan Wang, Anwen Xiong, Guanghui Gao, Bin Chen
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Advanced non-small cell lung cancer (NSCLC) patients harboring non-resistant uncommon epidermal growth factor receptor (EGFR) mutations have stepped into the era of targeted therapy. This study aimed to investigate the incidence of acquired T790M mut